ArticleJHLT open2026
Early clinical experience with a phase change material-based temperature-controlled cold-chain system for donor heart preservation.
Article in JHLT open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Temperature fluctuations during conventional ice-box static cold storage may contribute to donor heart injury. We evaluated a phase change material (PCM)-based temperature-controlled cold-chain container (VIXELL) in consecutive adult heart transplantations. Methods: In a single center, 12 consecutive orthotopic heart transplantations (May-Nov 2025) used VIXELL to maintain 2°C-8°C during ground transport with continuous temperature recording. Severe primary graft dysfunction (PGD) was assessed using International Society for Heart and Lung Transplantation criteria. Results: In-transit temperatures remained within 2°C-8°C in cases reflecting shorter and longer transport durations within the cohort without freezing or excessive warming. Cold ischemic time was 116.8 ± 59.6 min, and early graft function markers were favorable (peak lactate 6.3 ± 2.8 mmol/L; lactate normalization 13.8 ± 3.7 hours). No severe PGD occurred. Conclusions: PCM-based temperature control was feasible and provided stable hypothermia during donor heart transport. Larger comparative studies are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.